Huntington's Gene Therapy! - Replacing Microglia - fMRI Retraction
Breedlove, S
https://www.sciencenews.org/article/huntingtons-slowed-with-gene-therapy
In a first, Huntington’s disease is slowed by an experimental treatment
By Bethany Brookshire
Even hearing the phrase “Huntington’s disease” will make a room suddenly somber. So the joy that accompanied a recent announcement of results of an experimental gene therapy for the deadly diseases signaled an unfamiliar sense of hope.
In a small clinical trial, brain injections of a virus that codes for a tiny segment of RNA may have prevented the formation of the rogue proteins that make Huntington’s so devastating. The early results, announced September 24 in a news release, show that over three years, the treatment slowed Huntington’s progression by up to 75 percent. While not a cure, the treatment could potentially give people living with Huntington’s disease, who might otherwise face early disability and death, the gift of many more years of life.
“We’re doing science because it’s interesting and important, but we’re also in this game to save our friends and family from a horrible fate,” says Ed Wild, a neurologist at University College London. “That’s the most meaningful thing, looking my friends in the eye and [saying], ‘We did it.’”
Huntington’s disease currently has no effective treatments or cures. It is relatively rare, affecting about 7 out of every 100,000 people, and is the result of mutation in a single gene, appropriately called huntingtin. In the disease, that gene is mutated in only one way, making the front end of the resulting protein grow, says Russell Snell, a geneticist at the University of Auckland in New Zealand who was not involved in the study.
This expanded huntingtin is a protein gone toxic. It aggregates in the brain and kills cells largely in brain areas crucial for voluntary movements. Patients end up with increasing involuntary movements, stiffness, difficulties speaking and swallowing and cognitive decline. Huntington’s is genetically dominant — it takes only one copy of the defective gene to cause it — so a patient’s offspring have a 50 percent chance of inheriting the disease.
Wild and his colleagues, working with the Dutch pharmaceutical company uniQure, used microRNA — tiny segments of RNA that can trigger machinery to break down huntingtin RNA before it gets made into protein. Some other trials have tried simply injecting some of these RNAs, but have not succeeded, possibly because they were injected into the cerebrospinal fluid and couldn’t infiltrate the right areas of the brain.
This time, the scientists injected them directly into the brain, packaged inside a well-studied viral vector. The virus would “infect” neurons in the brain with the RNA, and “it basically reprograms the neuron to become a factory for a molecule that tells it not to make huntingtin protein,” Wild says.
© Society for Science & the Public 2000–2025.
--------------------
Huntington’s disease treated successfully for first time in UK gene therapy trial
Hannah Devlin Science correspondent
Huntington’s disease, a devastating degenerative illness that runs in families, has been treated successfully for the first time in a breakthrough gene therapy trial.
The disease, caused by a single gene defect, steadily kills brain cells leading to dementia, paralysis and ultimately death. Those who have a parent with Huntington’s have a 50% chance of developing the disease, which until now has been incurable.
The gene therapy slowed the progress of the disease by 75% in patients after three years.
Prof Sarah Tabrizi, the director of University College London’s Huntington’s disease centre, who led the trial, said: “We now have a treatment for one of the world’s more terrible diseases. This is absolutely huge. I’m really overjoyed.”
The drug, which inactivates the mutant protein that causes Huntington’s, is delivered to the brain in a single shot during a 12- to 20-hour surgical procedure, meaning that it will be expensive. The breakthrough is sending ripples of hope through the Huntington’s community, many of whom have witnessed the brutal impact of the disease on family members.
The first symptoms, which typically appear when the affected person is in their 30s or 40s, include mood swings, anger and depression. Later patients develop uncontrolled jerky movements, dementia and ultimately paralysis, with some people dying within a decade of diagnosis.
With treatment, people would be able to work and live independently for significantly longer, Tabrizi said, and the dramatic impact of the therapy raises the possibility that it could prevent symptoms occurring if given at an earlier stage.
© 2025 Guardian News & Media Limited
--------------------
https://www.nature.com/articles/d41586-025-03008-5
Swapping old immune cells in the brain with fresh ones could treat disease
Heidi Ledford
After a mouse received treatment to eliminate immune cells called microglia, it was injected with human progenitor cells that developed into human immune cells (green, pink and blue) in the animal’s brain.Credit: M. M.-D. Madler et al./Nature
A fresh supply of the immune cells that keep the brain tidy might one day help to treat a host of conditions, from ultra-rare genetic disorders to more familiar scourges, such as Alzheimer’s disease.
In the past few months, a spate of new studies have highlighted the potential of a technique called microglia replacement and explored ways to make it safer and more effective. “This approach is very promising,” says Pasqualina Colella, who studies gene and cell therapy at Stanford University School of Medicine in California. “But the caveat is the toxicity of the procedure.”
Microglia are immune cells that patrol the brain, gobbling up foreign invaders, damaged cells and harmful substances. They can help to protect neurons — cells that transmit and receive messages to and from other tissues — during seizures and strokes, and they prune unneeded connections between neurons during normal brain development.
“Microglia do a lot of important things,” says Chris Bennett, a psychiatrist who studies microglia at the Children’s Hospital of Philadelphia in Pennsylvania. “So, it’s not surprising that they are involved in the pathogenesis of many diseases.”
Those diseases include a suite of rare disorders caused by genetic mutations that directly affect microglia. Malfunctioning microglia have also been implicated in more familiar conditions with complex causes, such as Alzheimer’s disease and Parkinson’s disease, as well as ageing, says Bo Peng, a neuroscientist at Fudan University in Shanghai, China.
© 2025 Springer Nature Limited
--------------------
Authors retract Science paper on controversial fMRI method
By Calli McMurray
The authors behind a contentious 2022 Science paper that purported to measure neuronal activity using functional MRI (fMRI) retracted the work today.
The retraction marks the end of the road for the method, called “direct imaging of neuronal activity,” or DIANA, says Noam Shemesh, principal investigator at the Champalimaud Centre for the Unknown, who was not involved in the now-retracted work. But many neuroimaging researchers still hope to one day use fMRI to capture neuronal activity. “MRI is such a rich modality. It has such rich physics, and not all of it has been exploited in the functional sense,” Shemesh says.
DIANA collected fMRI data in a way that enabled the researchers to measure signal changes on the order of tens of milliseconds. The team, led by Jang-Yeon Park at Sungkyunkwan University, captured a signal peak in the somatosensory cortex of mice 25 milliseconds after shocking their whisker pads.
Despite an initial flurry of excitement from the field, other labs could not replicate the results. As a result, the paper received an editorial expression of concern in August 2023 because “the methods described in the paper are inadequate to allow reproduction of the results and … the results may have been biased by subjective data selection,” the notice states.
Following the editorial expression of concern, “we reanalyzed the data. Unfortunately, the additional results revealed unexpected MR signal characteristics and did not robustly support the original conclusions. We are therefore retracting the paper,” the retraction notice states. Science did not have any additional comment beyond what is outlined in the expression of concern and retraction notice.
© 2025 Simons Foundation
--------------------